Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
MBS2320 is a first-in-class investigational drug which is currently in clinical development for the treatment of rheumatoid arthritis (RA) where it has demonstrated a unique profile, reducing inflammation and supporting the remodelling of damaged bone.
Lead Product(s): MBS2320
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: MBS2320
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 05, 2022